MARKET

OLMA

OLMA

Olema Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.82
+0.91
+3.65%
After Hours: 25.82 0 0.00% 16:00 07/23 EDT
OPEN
25.13
PREV CLOSE
24.91
HIGH
26.54
LOW
24.36
VOLUME
303.71K
TURNOVER
--
52 WEEK HIGH
60.27
52 WEEK LOW
19.41
MARKET CAP
968.76M
P/E (TTM)
-41.4579
1D
5D
1M
3M
1Y
5Y
Biotech M&A may heat up with potential targets Horizon Therapeutics, Arrowhead Pharma, analyst says
janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to
Seekingalpha · 07/11 13:00
58 Biggest Movers From Friday
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.
Benzinga · 06/21 08:40
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 06/18 16:45
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 05/14 19:30
62 Biggest Movers From Yesterday
Gainers
Benzinga · 05/13 09:12
Olema Pharmaceuticals EPS misses by $0.11
Olema Pharmaceuticals (OLMA): Q1 GAAP EPS of -$0.39 misses by $0.11.Cash, cash equivalents and marketable securities of $326.97M.Press Release
Seekingalpha · 05/11 20:44
Olema Pharmaceuticals Q1 EPS $(0.39) Up From $(0.65) YoY
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.39) per share. This is a 40 percent increase over losses of $(0.65) per share from the same period last year.
Benzinga · 05/11 20:37
10-Q: OLEMA PHARMACEUTICALS, INC.
Edgar Online - (EDG = 10Q, 10K) · 05/11 20:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OLMA. Analyze the recent business situations of Olema Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OLMA stock price target is 58.33 with a high estimate of 60.00 and a low estimate of 55.00.
EPS
Institutional Holdings
Institutions: 74
Institutional Holdings: 35.86M
% Owned: 95.57%
Shares Outstanding: 37.52M
TypeInstitutionsShares
Increased
15
1.40M
New
32
708.98K
Decreased
13
1.46M
Sold Out
16
486.23K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Ian Clark
President/Chief Executive Officer/Director
Sean Bohen
Chief Financial Officer/Chief Operating Officer
Shane Kovacs
Executive Vice President/Secretary
John Moriarty
Chief Technology Officer/Director
Cyrus Harmon
Chief Scientific Officer
Peter Kushner
Other
Kinney Horn
Other
David Myles
Independent Director
Cynthia Butitta
Independent Director
Sandra Horning
Independent Director
Gorjan Hrustanovic
Independent Director
Yi Larson
Independent Director
Andrew Rappapor
Independent Director
Graham Walmsley
No Data
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN), and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It was designed by based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumour shrinkage in several xenograft models, including a breast cancer brain metastasis model.

Webull offers kinds of Olema Pharmaceuticals Inc stock information, including NASDAQ:OLMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OLMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OLMA stock methods without spending real money on the virtual paper trading platform.